Brief: Karyopharm Reports First Quarter 2023 Financial Results
May 4 (Reuters) - Karyopharm Therapeutics Inc KPTI.O :
* KARYOPHARM REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND
HIGHLIGHTS RECENT COMPANY PROGRESS
* NET LOSS OF $34.1 MILLION, OR $0.30 PER SHARE, FOR Q1 OF
2023
* Q1 EARNINGS PER SHARE VIEW $-0.37 -- REFINITIV IBES DATA
Source text for Eikon: ID:nPn2yycnXa
Further company coverage: KPTI.O
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview